Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 7
Submit an article Journal homepage
38
Views
5
CrossRef citations to date
0
Altmetric
Review

Perspectives on novel therapies for bronchial carcinoma

Fiona Blackhall Christie Hospital NHS Trust, Department of Medical Oncology, Wilmslow Road, Manchester, M20 4BX, UK. [email protected]
,
Pavlos I Papakotoulas Christie Hospital NHS Trust, Department of Medical Oncology, Wilmslow Road, Manchester, M20 4BX, UK. [email protected]
,
Sarah Danson Christie Hospital NHS Trust, Department of Medical Oncology, Wilmslow Road, Manchester, M20 4BX, UK. [email protected]
&
Nicholas Thatcher Christie Hospital NHS Trust, Department of Medical Oncology, Wilmslow Road, Manchester, M20 4BX, UK. [email protected]
Pages 1157-1167 | Published online: 15 Jun 2005

Bibliography

  • BUNN PA: Chemotherapy for advancednon-small cell lung cancer: who, what, when, why? J. Clin. Oncol (2002) 20:23s–33s.
  • SHEPHERD FA, FOSSELLA FV, LYNCH T et al.: Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two Phase III trials. Semin. Oncol (2001) 28(1 Suppl. 2):4–9.
  • •Comprehensive update on second-line therapy for NSCLC.
  • HANNA N, SHEPHERD FA, FOSSELLA FV et al.: Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol (2004) 22(9):1589–1597.
  • PAGE NC, READ WL, TIERNEY RM et al.: The epidemiology of small cell lung carcinoma. Proc. Am. Soc. Clin. Oncol. (2002) 21:305a (Abstract 1216).
  • HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell. (2000) 100(1):57–70.
  • ••An excellent overview ofmolecular oncology.
  • LOGRONO R, JONES DV, FARUQI S, BHUTANI MS: Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). Cancer Biol Ther. (2004) 3:251–258.
  • KAKLAMANI V, O'REGAN RM: New targeted therapies in breast cancer. Semin. Oncol (2004) 31(2 Suppl. 4):20–25.
  • IQBAL S, LENZ HJ: Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother. PharmacoL (2004) 54(1):532–539.
  • SHEPHERD FA, PEREIRA J, CIULEANU TE et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy; a National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial. 1 Clin. Oncol (2004) ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(145):7022.
  • ••First positive Phase III trial for a targetedagent in chemorefractory NSCLC.
  • MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy. Oncogene (2000) 19:6550–6565.
  • PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. Clin. Oncol (2004) 22:3238–3247.
  • FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 21:2237–2246.
  • KRIS MG, NATALE RB, HERBST RS et al.: Efficacy and safety of gefitinib (Iressa, ZD 1839), an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with advanced non-small-cell lung cancer. JAMA (2003) 290:2149–2158.
  • •Landmark study of survival in patients with stable disease.
  • NIHO S, KUBOTA K, GOTO K et al: First-line single agent of gefitinib in patients with advanced non-small cell lung cancer: a Phase II study. Proc. Am. Soc. Clin. Oncol (2004) 23:628 (Abstract 7059).
  • PEREZ-SOLER R, CHACHOUA A, HUBERMAN M et al.: A Phase II trial of the EGFR tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced, EGFR-expressing, non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol (2001) 20:310a (Abstract 1235).
  • PAEZ JG, JANNE PA, LEE JC et al.: EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5670:1497–1500.
  • •Report of mutations associated with gefitinib therapy.
  • MILLER VA, KRIS MG, SHAH N et al.: Broncioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol (2004) 22(6):1103–1109.
  • KIM YH, GOTO K, ISHII G et al: Association of papillary subtype of lung adenocarcinoma with response to gefitinib. Proc. Am. Soc. Clin. Oncol. (2004) 23:636 (Abstract 7092).
  • LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl. J. Med. (2004) 350:2129–2139.
  • •Report of mutations associated with gefitinib therapy.
  • PAO W, MILLER V ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Nail Acad. Sci. USA (2004) 101(36):13306–13311.
  • •Report of mutations associated with gefitinib and erlotinib therapy.
  • GIACCONE G, HERBST RS, MANEGOLD C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 1. Clin. Oncol (2004) 22(5):777–784.
  • HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2.1 Clin. Oncol (2004) 22(5):785–794.
  • GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:617 (Abstract 7010).
  • HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE-a Phase III trial of erlotinib (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:617 (Abstract 7011).
  • MILLER VA, HERBST R, PRAGER D et al.: Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HC1 (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. J. Clin. Oncol (2004) ASCO Annual Meeting Proceedings 22(14S):7061.
  • ROSELL R, DANIEL C, RAMLAU R et al.: Randomised Phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) versus CV alone in the first-line treatment of patients with EGFR-expressing advanced non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol (2004) 23:618 (Abstract 7012).
  • KIM ES, MAUER AM, TRAN HT et al:A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc. Am. Soc. Clin. Oncol (2003) 22:642.
  • LYNCH TJ, LILENBAUM R, BONOMI P et al.: A Phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2004) 23:637.
  • MEERT AP, MARTIN B, PAESMANS M et al: The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br. J. Cancer (2003) 89:959–965.
  • GATZEMEIER U, GROTH G, BUTTS C et al.: Randomised Phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. (2004) 15:19–27.
  • LANGER CJ, STEPHENSON P, THOR A et al.: Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. Clin. Oncol (2004) 22(7):1180–1187.
  • BLACKHALL FH, SHEPHERD FA: Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. Hematol/Oncol Clin. N America (2004) 18:1121–1141.
  • JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomised Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol (2004) 22(11):2184–2191.
  • SMYLIE M, MERCIER R, ABOULAFIA D et al: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:307a (Abstract 1226).
  • BISSETT D, O'BYRNE K, VON PAWEL J et al: Phase III study of the matrix metalloproteinase inhibitor prinomastat in combination with gemcitibine and cisplatin in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:296a (Abstract 1183).
  • FALARDEAU P, CHAMPAGNE P, POYET P, HARITON C, DUPONT E: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in Phase III clinical trials. Semin. Oncol (2001) 289(6):620–625.
  • D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA (1994) 91(9):4082–4085.
  • MERCHANT J, HAMMES L, LARSON M et al.: Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2000)18:541a (Abstract 2130).
  • WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62(161:4645–4655.
  • JOHNSON BE, HEYMACHJV: Farnesyl tranferase inhibitors for patients with lung cancer. Clin. Cancer Res. (2004) 10:4254s–4257s.
  • ADJEI AA, MAUER A, BRUZEK L et aL:Phase II study of the farnesyl tranferase inhibitor R115777 in patients with advanced non-small cell lung cancer. J. Clin. Oncol. (2003) 21:1760–1766.
  • KHURI FR, RIGAS JR, FIGLIN RA et al: Multi-institutional Phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2001) 15:2626–2637.
  • RIZVI N, HAWKINS MJ, EISENBERG PD et al.: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin. Lung Cancer (2001) 2:210–215.
  • SCHEINEMACHERS D, EVERSON R: Aspirin use and lung, colon, breast cancer incidence in a prospective study. Epidemiology (1994) 5:138–146.
  • ALTORKI NK, KERESZTES RS, PORT JL et al.: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J. Clin. Oncol (2003) 21:2645–2650.
  • SOLOMON SD, MCMURRAY JJ, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl. J. Med. (2005) 352(11):1071–1080.
  • YUEN A, HALSEY J, FISHER G et al: Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:309a.
  • LYNCH TJ, RAJU R, LIND M et al: Randomized Phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report Proc. Am. Soc. Clin. Oncol (2003) 22:623 (Abstract 2504).
  • BLACKHALL FH, PINTILIE M, MICHAEL M et al.: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin. Cancer Res. (2003) 9(6):2241–2247.
  • MURRAY N, SALGIA R, FOSSELA F: Targeted molecules in small cell lung cancer. Semin. Oncol. (2004) 31(1 Suppl. 1):106–111
  • JOHNSON BE, FISCHER T, FISCHER B et al: Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. (2003) 9:5880–5887.
  • KRUG LM, CRAPANZANO JP, MILLER VA et al: C-kit protein expression in tumour specimens as a predictor of sensitivity to imatinib mesylate in patients with small cell lung cancer: a Phase II clinical trial. Proc. Am. Soc. Clin. Oncol (2004) 23:667 (Abstract 7218).
  • BROWN PD, GIAVAZZI R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol (1995) 6(14967–974.
  • SHEPHERD FA, GIACCONE G, SEYMOUR Let al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the national cancer institute of Canada-clinical trials group and the European organization for research and treatment of cancer. Clin. Oncol. (2002) 20(22):4434–4439.
  • ERLICHMAN C, ADJEI AA, ALBERTS SR et al: Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann. Oncol (2001) 12(3):389–395.
  • HURWITZ H, HOLDEN SN, ECKHARDT SG et al: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21:82a (Abstract 325).
  • LEE SM, JAMES LE, MOHAMED-ALI V et al: A Phase II study of carboplatin/ etoposide with thalidomide in small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:313a.
  • QUANTIN X, JACOT W, BOZONNAT MC: Abstracts of the 8th Central European Lung Cancer Conference. 1–4 September 2002. Vienna, Austria. (2002) 37 (Suppl. 1):546.
  • RUDIN CM, KOZLOFF M, HOFFMAN PC et al: Phase I study of G3139, a bc1-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. Clin. Oncol. (2004) 22:1110–1117.
  • GRANT SC, KRIS MG, HOUGHTON AN, CHAPMAN PB: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. (1999) 6:1319–1323.
  • GIACCONE G, DEBRUYNE C, FELIP E et al.: Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study)J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). (2004) 22(14S):7020.
  • MA BB, BRITTEN CD, SIU LL: Clinicaltrial designs for targeted agents. Hematol Oncol Clin. North Am. (2002) 16(5):1287–1305.
  • DANSON S, BLACKHALL F, HULSE P, RANSON M: Interstitial lung disease in lung cancer: separating the effect of the disease from its treatment. Drug Sal: (2005) 28(2):103–113.
  • •Overview of interstitial lung disease caused by EGFR inhibitors.
  • HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J. Clin. Oncol (2005) 23(11):2544–2555
  • GADGEEL SM, SHEHADEH NJ, RUCKDESCHEL JC et al.: Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:636 (Abstract 7094).

Websites

  • http://www.astrazeneca.com/pressrelease/ 4245.aspx AstraZeneca Press Release: Gefitinib (Iressa) lung cancer ISEL trial shows no overall survival advantage in a highly refractory population. December 17 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.